Abiopharma

🔍 Brown Hayden (Executive)

Company: UPWORK, INC (UPWK)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Acquired 14,850 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 812,345.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 18,333 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 830,678.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 13,639 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 844,317.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 23,241 shares of Common Stock at $8.4257 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 821,076.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 50,000 shares of Common Stock at $8.4271 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 771,076.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 14,850 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 29,700.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
• Sold 18,333 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 36,667.00 | transaction_form_type: 4 | Footnotes: F1, F7, F7
• Sold 13,639 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 190,944.00 | transaction_form_type: 4 | Footnotes: F1, F8, F8

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
• F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $8.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 19, 2025.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.245 to $8.52 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The RSUs vest 25% on February 18, 2024, and then 6.25% of the total shares vest on each quarterly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each vesting date.
• F7: The RSUs vest in equal quarterly installments over four years beginning on May 18, 2023, subject to the continuing employment of the Reporting Person with the Issuer on each vesting date.
• F8: The RSUs vest in equal quarterly installments over four years beginning on May 18, 2026, subject to the continuing employment of the Reporting Person with the Issuer on each vesting date.